Oxford, UK, 29 June 2012 – Summit (AIM: SUMM), a UK drug discovery company, will today be
presenting its SMT C1100 programme for the treatment of the fatal genetic disease Duchenne
Muscular Dystrophy (‘DMD’), at the annual Connect Conference, 28 June-1 July in Fort Lauderdale,
US. The conference is hosted by the organisation Parent Project Muscular Dystrophy (‘PPMD’).
A copy of the presentation is available on request from email@example.com.
Summit will also participate alongside key clinical investigators and industry representatives in a
closed-session panel discussion on the design and implementation of future patient clinical trials.
The Connect meeting has evolved into the largest, most comprehensive international conference
focused on DMD and brings together the DMD community with attendees including leading
physicians, researchers and families.
About SMT C1100
SMT C1100 is a potential disease-modifying small molecule drug that works by increasing, or
upregulating, the amount of a naturally occurring protein called utrophin. Utrophin is a protein that is
highly expressed in regenerating muscle, but decreases as the muscle fibre matures and is eventually
replaced by dystrophin, a protein that maintains the integrity and healthy function of muscles.
Patients with DMD are unable to make dystrophin, resulting in muscle fibre degeneration. However, if
utrophin is continually expressed in the mature muscle fibre, it can replace the function of dystrophin
and thereby overcome the deficit in patients with DMD.
SMT C1100 is currently in a Phase 1 dose-escalation study in healthy volunteers with results from the
trial expected by the end of this year. The trial is supported by a $1.5 million agreement with a group
of US-based DMD organisations. Utrophin upregulation is expected to be a universal treatment for all
DMD patients regardless of whether the disease was caused by an inherited or spontaneous genetic
mutation. Summit has demonstrated in non-clinical efficacy studies that SMT C1100 is capable of
increasing utrophin to restore and maintain the healthy function of muscles.
For more information, please contact:
Glyn Edwards / Richard Pye
Tel: +44 (0)1235 443 939
Singer Capital Markets
(Nominated Adviser and Joint broker)
Shaun Dobson / Claes Spång
Tel: +44 (0)203 205 7500
Claire Louise Noyce / Deepak Reddy
Tel: +44 (0)207 947 4350
(Financial public relations, UK)
Tel: +44 (0)7879 458 364
MacDougall Biomedical Communications
(U.S. media contact)
Tel: +1 781-235-3060
Duchenne muscular dystrophy is a fatal genetic neuromuscular disorder that affects 1 in 3,500 boys
with an estimated patient population of 50,000 in the developed world. The disease is caused by
defects in the gene required to make dystrophin, a protein, which maintains the integrity and healthy
function of muscles. One in three new cases are due to a spontaneous mutation where there is no
familial history of the disease. The progressive muscle wasting begins in early childhood and typically
leads to death in the twenties due to cardiac and respiratory failure. Currently there is no cure for the
About Parent Project Muscular Dystrophy
Parent Project Muscular Dystrophy (PPMD) is a national not-for-profit organization founded in 1994 by
parents of children with Duchenne and Becker muscular dystrophy. Our mission is to end Duchenne.
We accelerate research, raise our voices in Washington, demand optimal care for all young men, and
educate the global community. PPMD is headquartered in Middletown, Ohio with offices in Fort Lee,
New Jersey. For more information, visit www.ParentProjectMD.org.
Summit is an Oxford, UK based drug discovery Company with an innovative Seglin™ technology
platform for the discovery of new medicines and a portfolio of drug programme assets. Summit’s
programme portfolio consists of a number of drug programmes targeting high-value areas of unmet
medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on
the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further
information is available at www.summitplc.com.